Obama's Gift To The Biotech Industry

Obama's Gift To The Biotech Industry


If a drug has already been approved by the FDA, firms can rely on real world evidence to seek approval for additional indications. Clinical trials are incredibly expensive and the ability to rely on data collected outside traditional drug trials presents an incredible cost savings opportunity.



from Biotech News